Siemens Healthineers, Varian demonstrate commitment to embracing innovation and enhancing outcomes at ASTRO 2023

Press releases may be edited for formatting or style | September 29, 2023 Rad Oncology
PALO ALTO, Calif., Sept. 28, 2023 /PRNewswire/ -- Varian, a Siemens Healthineers company, is showcasing technologies that reflect its continued commitment to embracing innovation and enhancing outcomes for cancer patients at this year's 2023 American Society for Radiation Oncology (ASTRO) annual meeting, taking place from October 1-4 in San Diego, California.

Cancer care is complex, and providers worldwide are forced to navigate the challenges of fragmented healthcare delivery systems. As a Siemens Healthineers company, Varian is building on its legacy as a radiotherapy leader and evolving to enable comprehensive cancer care by providing innovative, increasingly integrated solutions.

"Radiotherapy is a vital part of most cancer patients' treatment and, thanks to the collaboration and input Varian users have provided, our technology has advanced significantly over the past couple of decades," said Arthur Kaindl, Head of Varian. "At Varian, we see tremendous opportunities to build on our leadership in radiotherapy and advance our mission to help create a world without fear of cancer. We are confident that our continued investment in innovation along the entire cancer care continuum will allow providers to treat more patients in need, more efficiently, earlier in their cancer journey – ultimately, creating the opportunity to enhance outcomes for patients around the world."

The solutions Varian will be highlighting at ASTRO support the company's commitment to embracing innovation and enhancing outcomes by:

Connecting the power of imaging

By joining forces with Siemens Healthineers, a global leader in imaging, Varian is working to expand its imaging capabilities to provide solutions with improved accuracy and quality. Examples that will be showcased at ASTRO include:

The HyperSight imaging solution, available on Ethos and Halcyon radiotherapy systems, is now pending FDA 510(k) clearance for use on the TrueBeam and Edge radiotherapy systems. HyperSight imaging is the next generation of in-room imaging, providing users access to better image quality, more precise images with greater contrast, and speed with shorter image acquisition time, compared to Varian's conventional linear-accelerator based imaging systems.
Ethos therapy combines the innovations of adaptive therapy with the flexibility to perform conventional radiotherapy treatments on a single linac. The latest release* provides dose calculation on high-quality CBCT imaging when used with the HyperSight imaging option, extended AI segmentation for both offline and online workflows, as well as enhanced communication with ARIA OIS.

You Must Be Logged In To Post A Comment